These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17538153)

  • 1. Complete, long-standing regression of hepatocellular carcinoma after somatostatin analogue treatment.
    Rahmi G; Malka D; Tomasic G; Dromain C; Ducreux M; Boige V
    J Clin Oncol; 2007 Jun; 25(16):e15-6. PubMed ID: 17538153
    [No Abstract]   [Full Text] [Related]  

  • 2. [Somatostatin analogue (octreotide)].
    Sano K; Makuuchi M
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():674-7. PubMed ID: 11762035
    [No Abstract]   [Full Text] [Related]  

  • 3. Complete regression of hepatocellular carcinoma under tamoxifen.
    Castéra L; Boige V; Rocher L; Duclos-Vallée JC; Fabre M; Buffet C
    Am J Gastroenterol; 2000 Mar; 95(3):827-9. PubMed ID: 10710095
    [No Abstract]   [Full Text] [Related]  

  • 4. Somatostatin analogs and hepatocellular carcinoma: Not dead yet?
    Raftery L; O'Neil BH
    Cancer Biol Ther; 2009 Nov; 8(21):2040-1. PubMed ID: 19823044
    [No Abstract]   [Full Text] [Related]  

  • 5. Octreotide in hepatocellular carcinoma.
    Shouval D
    Gut; 1998 Mar; 42(3):316-7. PubMed ID: 9577332
    [No Abstract]   [Full Text] [Related]  

  • 6. Regression of a hepatocellular carcinoma following treatment with octreotide and tamoxifen in a patient with advanced alcoholic cirrhosis.
    Senturk H; Canbakan B; Cumali R
    J Gastroenterol Hepatol; 2004 Jun; 19(6):719-20. PubMed ID: 15151636
    [No Abstract]   [Full Text] [Related]  

  • 7. Octreotide and hepatocellular carcinoma.
    Farinati F; Sergio A; Baldan A; Zucchetta P; Corleto VD
    Br J Cancer; 2007 Jun; 96(11):1778-9. PubMed ID: 17505506
    [No Abstract]   [Full Text] [Related]  

  • 8. [A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Hepatocellular Carcinoma: Treatment with Octreotide].
    Allgaier HP; Becker G; Blum HE
    Dtsch Med Wochenschr; 2000 Mar; 125(11):320. PubMed ID: 10761474
    [No Abstract]   [Full Text] [Related]  

  • 9. [Tamoxifen and hepatocarcinoma].
    Mondragón Sánchez R
    Rev Gastroenterol Mex; 1998; 63(3):169. PubMed ID: 10068765
    [No Abstract]   [Full Text] [Related]  

  • 10. Octreotide treatment of hepatocellular carcinoma.
    Kouroumalis E; Samonakis D; Skordilis P
    Hepatology; 2003 Feb; 37(2):477. PubMed ID: 12540801
    [No Abstract]   [Full Text] [Related]  

  • 11. Octreotide for unresectable hepatocellular carcinoma: beyond the first sight.
    Samonakis DN; Christodoulakis N; Kouroumalis EA
    J Clin Gastroenterol; 2006 Jan; 40(1):86-7. PubMed ID: 16340641
    [No Abstract]   [Full Text] [Related]  

  • 12. Somatostatin and hepatocellular carcinoma.
    Kapadia CR
    Gastroenterology; 1998 Nov; 115(5):1298-9. PubMed ID: 9797392
    [No Abstract]   [Full Text] [Related]  

  • 13. Octreotide inhibits the growth and development of three types of experimental liver metastasis.
    Frizelle FA
    Br J Surg; 1995 Nov; 82(11):1577. PubMed ID: 8535822
    [No Abstract]   [Full Text] [Related]  

  • 14. [Chemotherapy of hepatocytoma--discrepancies between AFP activity and the progress of the disease].
    Imaeda T; Suzuki M; Matayoshi J; Doi H
    Rinsho Hoshasen; 1979; 24(2):335-6. PubMed ID: 85732
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.
    Kouroumalis E; Skordilis P; Thermos K; Vasilaki A; Moschandrea J; Manousos ON
    Gut; 1998 Mar; 42(3):442-7. PubMed ID: 9577356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Megestrol treatment in patients with hepatocellular carcinoma.
    Farinati F; Gianni S; De Giorgio M; Fiorentini S
    Br J Cancer; 2001 Nov; 85(10):1606-8. PubMed ID: 11720452
    [No Abstract]   [Full Text] [Related]  

  • 17. Complete regression of advanced HCC with long acting octreotide.
    Siveke JT; Herberhold C; Folwaczny C
    Gut; 2003 Oct; 52(10):1531. PubMed ID: 12970151
    [No Abstract]   [Full Text] [Related]  

  • 18. Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent.
    Chen LT; Shiah HS; Chao Y; Chang JY; Cheng LT; Whang-Peng J
    J Clin Oncol; 2009 Dec; 27(36):e271; author reply e272. PubMed ID: 19917866
    [No Abstract]   [Full Text] [Related]  

  • 19. A dramatic response to long-acting octreotide in metastatic hepatocellular carcinoma.
    Deming DA; Stella AL; Holen KD; Ku G; O'Reilly EM
    Clin Adv Hematol Oncol; 2005 Jun; 3(6):468-72; discussion 472-4. PubMed ID: 16167024
    [No Abstract]   [Full Text] [Related]  

  • 20. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.
    Cebon J; Findlay M; Hargreaves C; Stockler M; Thompson P; Boyer M; Roberts S; Poon A; Scott AM; Kalff V; Garas G; Dowling A; Crawford D; Ring J; Basser R; Strickland A; Macdonald G; Green M; Nowak A; Dickman B; Dhillon H; Gebski V;
    Br J Cancer; 2006 Oct; 95(7):853-61. PubMed ID: 16953241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.